On 28 June 2019, orphan designation EU/3/19/2169 was granted by the European Commission to Pharma Gateway AB, Sweden, for reldesemtiv for the treatment of spinal muscular atrophy.
|Disease / condition||
Treatment of spinal muscular atrophy
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: